Document is current
Any future updates will be listed below
-
Authors
Al-Laith, Mariam http://orcid.org/0000-0001-6043-2006
Jasenecova, Marianna
Abraham, Sonya
Bosworth, Aisla
Bruce, Ian N.
Buckley, Christopher D.
Ciurtin, Coziana
D’Agostino, Maria-Antonietta
Emery, Paul
Gaston, Hill
Isaacs, John D.
Filer, Andrew
Fisher, Benjamin A.
Huizinga, Thomas W. J.
Ho, Pauline
Jacklin, Clare
Lempp, Heidi
McInnes, Iain B.
Pratt, Arthur G.
Östor, Andrew
Raza, Karim
Taylor, Peter C.
van Schaardenburg, Dirkjan
Shivapatham, Dharshene
Wright, Alison J.
Vasconcelos, Joana C.
Kelly, Joanna
Murphy, Caroline
Prevost, A. Toby
Cope, Andrew P.
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (IMI101-328)
- License Information
-
More Information
Article History
Received: 5 December 2018
Accepted: 6 May 2019
First Online: 15 July 2019
Ethics approval and consent to participate
: This clinical trial has been approved by the London – Westminster National Research Ethics Service (NRES) Committee (reference 14/LO/0100), the Health Research Authority (HRA) (reference 135429) and the Medicines and Healthcare products Regulatory Agency for clinical trial authorisation (reference 28482/0012/001–0001). The ethics committee approved all amendments and study extensions. Ethical approval has also been obtained from the University Hospital Executive Boards in the Netherlands relevant to all participating sites. Informed written consent will be obtained from all participants prior to recruitment to the study.
: Not applicable.
: MA-L, MJ, SA, AB, CC, HG, AF, BAF, PH, CJ, HL, DvS, DS, AJW, JCV, JK, CM and ATP declare that they have no competing interests relating to this study. INB, CDB, M-AD’A, PE, TWJH, JDI, IBM, AÖ, AGP, KR, PCT, and APC have received honoraria, speaker fees or research funding (or a combination of these) from Bristol-Myers Squibb or from other pharmaceutical companies.
